Investigators evaluated the incidence of asymptomatic cerebral emboli and cognitive outcomes in patients receiving pulsed field ablation for AF.

Q1 2026 Management View “This is an exciting day as it represents our first analyst call reporting on our first ever quarter or, more accurately, partial quarter of sales since the commercial launch ...

Unlike traditional dyes used for CT and MRI scans, they aren’t toxic to the kidneys, and there’s a lower risk of allergic ...

CARDAMYST™ (etripamil) nasal spray launch for PSVT is gaining traction; breadth of unique prescribers supports potential future adoptionExpress Scripts national formulary coverage secured as company ...

Researchers at Ben-Gurion University of the Negev (BGU) have identified how two different classes of medication—the GLP-1 ...

Subgroup analyses suggest an individualized approach may be helpful, but the findings are not definitive, one expert says.

In early May 2026, Pulse Biosciences reported a wider first-quarter net loss of US$18.58 million and basic loss per share of US$0.27, while highlighting strong European feasibility data for its nPulse ...

Atrial fibrillation is the most common arrythmia, affecting nearly one in 20 Americans. For a future story, the Globe is ...